• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Anika Therapeutics Inc.

    4/28/26 4:51:03 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email
    DEFA14A 1 ny20067128x2_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A
    (Rule 14a-101)
    INFORMATION REQUIRED IN PROXY STATEMENT
    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

    Filed by the Registrant ☒       Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐
    Preliminary Proxy Statement
       
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐
    Definitive Proxy Statement
       
    ☒
    Definitive Additional Materials
       
    ☐
    Soliciting Material Pursuant to §240.14a-12

    Anika Therapeutics, Inc.
    (Name of Registrant as Specified in its Charter)

    Not applicable.
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):
       
    ☒
    No fee required.
       
    ☐
    Fee paid previously with preliminary materials.
       
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.






    Get the next $ANIK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    SEC Filings

    View All

    SEC Form DEFA14A filed by Anika Therapeutics Inc.

    DEFA14A - Anika Therapeutics, Inc. (0000898437) (Filer)

    6/1/26 11:12:52 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Anika Therapeutics Inc.

    10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)

    4/29/26 7:47:37 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

    4/29/26 7:20:27 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Henneman John B Iii bought $73,320 worth of shares (5,000 units at $14.66), increasing direct ownership by 10% to 54,871 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    5/4/26 8:34:30 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    President and CEO Griffin Stephen D. bought $149,881 worth of shares (12,200 units at $12.29), increasing direct ownership by 51% to 36,163 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    4/30/26 5:22:40 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

    MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,

    4/30/26 4:43:11 PM ET
    $ACRX
    $ANIK
    $AXGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Anika Reports First Quarter 2026 Financial Results

    Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation generating early wins, delivering $4 million of adjusted EBITDA BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026. Total revenue for the first quarter of 2026 was $29.6 million, compared to $26.2 million in the prior-ye

    4/29/26 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

    WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. "Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board," said Sara Bonstein, chair of the board of direct

    4/16/26 7:30:00 AM ET
    $ANIK
    $XLO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

    B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Anika Therapeutics with a new price target

    Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

    11/1/24 10:25:08 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics upgraded by Barrington Research with a new price target

    Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

    8/14/23 9:16:10 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Henneman John B Iii bought $73,320 worth of shares (5,000 units at $14.66), increasing direct ownership by 10% to 54,871 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    5/4/26 8:34:30 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    President and CEO Griffin Stephen D. bought $149,881 worth of shares (12,200 units at $12.29), increasing direct ownership by 51% to 36,163 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    4/30/26 5:22:40 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Mcleod Ian

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    3/23/26 5:23:05 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Leadership Updates

    Live Leadership Updates

    View All

    Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

    WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. "Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board," said Sara Bonstein, chair of the board of direct

    4/16/26 7:30:00 AM ET
    $ANIK
    $XLO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors

    NEWTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies. Dr. Blanchard most recently served as President, CEO, and Director of Anika Therapeutics (NASDAQ:ANIK), where she led the successful implementat

    2/4/26 8:54:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Announces Leadership Transition

    Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griff

    1/8/26 7:00:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Anika Therapeutics Inc.

    SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/8/24 2:17:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    5/30/24 4:31:25 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    3/6/24 7:30:09 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Financials

    Live finance-specific insights

    View All

    Anika Reports First Quarter 2026 Financial Results

    Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation generating early wins, delivering $4 million of adjusted EBITDA BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026. Total revenue for the first quarter of 2026 was $29.6 million, compared to $26.2 million in the prior-ye

    4/29/26 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026

    BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 82141. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.an

    4/15/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Reports Fourth Quarter and Full Year 2025 Financial Results

    Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 3

    2/26/26 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care